Sleep disturbance in patients with cirrhosis and transjugular intrahepatic portosystemic shunt.
Humans
Portasystemic Shunt, Transjugular Intrahepatic
/ adverse effects
Female
Male
Middle Aged
Liver Cirrhosis
/ complications
Hepatic Encephalopathy
/ etiology
Sleep Wake Disorders
/ etiology
Prospective Studies
Aged
Postoperative Complications
/ epidemiology
Quality of Life
Sleep Quality
Incidence
Risk Factors
Adult
Cirrhosis
Sleep disturbance
Transjugular intrahepatic portosystemic shunt
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
received:
05
07
2024
accepted:
18
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
epublish
Résumé
Sleep disturbance (SD) is a common occurrence in individuals with cirrhosis and significantly impacts their quality of life. Datas regarding post transjugular intrahepatic portosystemic shunt (TIPS) SD are scarce. This study aimed to explore the incidence and outcomes of post-TIPS SD. From August 2018 to November 2019, 73 patients who underwent TIPS were prospectively recruited for the study. Sleep quality was evaluated via the Pittsburgh Sleep Quality Index (PSQI), and the presence of hepatic encephalopathy was evaluated according to the West Haven criteria before and after the TIPS procedure. Nineteen patients (26%) experienced new-onset SD after TIPS, with a median latency of 67 (40-98) days from the procedure. The median time from TIPS creation to occurrence was 67 (40-98) days. Minimal hepatic encephalopathy (MHE) post-TIPS emerged as an independent predictor of SD, with an odds ratio of 3 (95% CI: 1.04-8.78, P = 0.046). Notably, five of the six (83%) patients with SD experienced improvement after being administered eszopiclone. Ten of the thirteen (77%) patients with SD improved spontaneously without treatment. Furthermore, the prevalence of MHE was significantly greater among patients with SD than among those without SD (58% vs. 31%, P = 0.04). SD is prevalent in patients who undergo TIPS. MHE is an independent risk factor for the development of SD post-TIPS. Eszopiclone may be a safe and effective treatment option for patients with SD after TIPS. The study was registered with ClinicalTrials.gov under the identifier NCT03685994, with a registration date of September 23, 2018.
Sections du résumé
BACKGROUND
BACKGROUND
Sleep disturbance (SD) is a common occurrence in individuals with cirrhosis and significantly impacts their quality of life. Datas regarding post transjugular intrahepatic portosystemic shunt (TIPS) SD are scarce. This study aimed to explore the incidence and outcomes of post-TIPS SD.
METHODS
METHODS
From August 2018 to November 2019, 73 patients who underwent TIPS were prospectively recruited for the study. Sleep quality was evaluated via the Pittsburgh Sleep Quality Index (PSQI), and the presence of hepatic encephalopathy was evaluated according to the West Haven criteria before and after the TIPS procedure.
RESULTS
RESULTS
Nineteen patients (26%) experienced new-onset SD after TIPS, with a median latency of 67 (40-98) days from the procedure. The median time from TIPS creation to occurrence was 67 (40-98) days. Minimal hepatic encephalopathy (MHE) post-TIPS emerged as an independent predictor of SD, with an odds ratio of 3 (95% CI: 1.04-8.78, P = 0.046). Notably, five of the six (83%) patients with SD experienced improvement after being administered eszopiclone. Ten of the thirteen (77%) patients with SD improved spontaneously without treatment. Furthermore, the prevalence of MHE was significantly greater among patients with SD than among those without SD (58% vs. 31%, P = 0.04).
CONCLUSIONS
CONCLUSIONS
SD is prevalent in patients who undergo TIPS. MHE is an independent risk factor for the development of SD post-TIPS. Eszopiclone may be a safe and effective treatment option for patients with SD after TIPS. The study was registered with ClinicalTrials.gov under the identifier NCT03685994, with a registration date of September 23, 2018.
Identifiants
pubmed: 39465397
doi: 10.1186/s12876-024-03470-x
pii: 10.1186/s12876-024-03470-x
doi:
Banques de données
ClinicalTrials.gov
['NCT03685994']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
381Informations de copyright
© 2024. The Author(s).
Références
Córdoba J, Cabrera J, Lataif L, et al. High prevalence of sleep disturbance in cirrhosis. Hepatology. 1998;27:339–45.
doi: 10.1002/hep.510270204
pubmed: 9462628
Bianchi G, Marchesini G, Nicolino F, et al. Psychological status and depression in patients with liver cirrhosis. Dig Liver Dis. 2005;37:593–600.
doi: 10.1016/j.dld.2005.01.020
pubmed: 15869912
Mostacci B, Ferlisi M, Baldi Antognini A, et al. Sleep disturbance and daytime sleepiness in patients with cirrhosis: a case control study. Neurol Sci. 2008;29:237–40.
doi: 10.1007/s10072-008-0973-7
pubmed: 18810597
Montagnese S, Middleton B, Skene DJ, et al. Night-time sleep disturbance does not correlate with neuropsychiatric impairment in patients with cirrhosis. Liver Int. 2009;29:1372–82.
doi: 10.1111/j.1478-3231.2009.02089.x
pubmed: 19686311
De Cruz S, Espiritu JR, Zeidler M, et al. Sleep disorders in chronic liver disease. Semin Respir Crit Care Med. 2012;33:26–35.
doi: 10.1055/s-0032-1301732
pubmed: 22447258
Montagnese S, De Pitta C, De Rui M, et al. Sleep-wake abnormalities in patients with cirrhosis. Hepatology. 2014;59:705–12.
doi: 10.1002/hep.26555
pubmed: 23744627
Formentin C, Garrido M, Montagnese S. Assessment and management of sleep disturbance in cirrhosis. Curr Hepatol Rep. 2018;17:52–69.
doi: 10.1007/s11901-018-0390-1
pubmed: 29876197
pmcid: 5966474
Shah NM, Malhotra AM, Kaltsakas G. Sleep disorder in patients with chronic liver disease: a narrative review. J Thorac Dis. 2020;12:S248–60.
doi: 10.21037/jtd-cus-2020-012
pubmed: 33214928
pmcid: 7642630
Montagnese S, Middleton B, Mani AR, et al. Sleep and circadian abnormalities in patients with cirrhosis: features of delayed sleep phase syndrome? Metab Brain Dis. 2009;24:427–39.
doi: 10.1007/s11011-009-9146-5
pubmed: 19756996
Bersagliere A, Raduazzo ID, Nardi M, et al. Induced hyperammonemia may compromise the ability to generate restful sleep in patients with cirrhosis. Hepatology. 2012;55:869–78.
doi: 10.1002/hep.24741
pubmed: 21994139
Rossle M. TIPS: 25 years later. J Hepatol. 2013;59:1081–93.
doi: 10.1016/j.jhep.2013.06.014
pubmed: 23811307
Dariushnia SR, Haskal ZJ, Midia M, et al. Quality improvement guidelines for transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol. 2016;27:1–7.
doi: 10.1016/j.jvir.2015.09.018
pubmed: 26614596
Wiltfang J, Nolte W, von Heppe J, et al. Sleep disorders and portal-systemic encephalopathy following transjugular intrahepatic portosystemic stent shunt in patients with liver cirrhosis. Adv Exp Med Biol. 1999;467:172–6.
Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193–213.
doi: 10.1016/0165-1781(89)90047-4
pubmed: 2748771
Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial Gastroenterology. 1977;72:573–83.
pubmed: 14049
Wechsler DW. Adult Intelligence Scale. New York: Psychological Corporation; 1955.
Ho C. Trail making and number-connection tests in the assessment of mental state in portal systemic encepha lopathy. Am J Dig Dis. 1977;22:541–50.
doi: 10.1007/BF01072510
Hamilton W. Neuropsychologie der letenten hepatischen en zephalopathie. Habilitationsschrift, Tubingen: Universitat Tubingen; 1983.
Schomerus H, Weissenborn K, Hamster W, et al. PSE-Syndrome-test, swets test services. Frank furt: Swets & Zeitlinger BV; 1999.
Zeng X, Zhang LY, Liu Q, et al. Combined scores from the EncephalApp stroop test, number connection test B, and serial dotting test accurately identify patients with covert hepatic encephalopathy. Clin Gastroenterol Hepatol. 2020;18(1618–1625):e1617.
Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–5.
doi: 10.1111/j.2044-8341.1959.tb00467.x
pubmed: 13638508
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
doi: 10.1136/jnnp.23.1.56
pubmed: 14399272
pmcid: 495331
De Silva AP, Niriella MA, Ediriweera DS, et al. Low-dose melatonin for sleep disturbances in early-stage cirrhosis: A randomized, placebo-controlled, cross-over trial. JGH Open. 2020;4:749–56.
doi: 10.1002/jgh3.12356
pubmed: 32782966
pmcid: 7411556
Sharma MK, Kainth S, Kumar S, et al. Effects of zolpidem on sleep parameters in patients with cirrhosis and sleep disturbances: A randomized, placebo-controlled trial. Clin Mol Hepatol. 2019;25:199–209.
doi: 10.3350/cmh.2018.0084
pubmed: 30856689
pmcid: 6589852